Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSET seals $11m financing:

This article was originally published in Clinica

Executive Summary

BioSurface Engineering Technologies (BioSET), a developer of synthetic peptide growth factors for advanced tissue repair, has completed an $11m financing round. The company intends to use the funds to commence human clinical trials of its synthetic B2A growth factor product for spine fusion, and to advance pre-clinical development of further products. The financing was led by PTV Sciences and included the participation of new investors Westfield Capital and Heron Capital, and existing shareholders Vertical Group, EDF Ventures MB Ventures and New Markets Growth Fund. According to industry analysts, the US market for growth factor-based bone graft products was more than $650m in 2006, with an annual growth rate of 33%. The estimated bone substitute materials market in 2006 is approximately $1.4bn.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel